NCT03529227 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

??? ???
?.?. ???????, ?.?. ???????????, ?.?. ????????, "??????????????? ??????????????? ? ?????? ? 2015 ???? (?????????????? ? ??????????)" - ?.: ????? ??. ?.?. ??????? - ?????? ???? "?????" ????????? ?????? - 2017. - ??. - 250 ?. ISBN 978-5-85502-227-8.
?????????? ??????????? ???????????? ?? ??????????? ? ??????? ???????????????????? ???????????
??? ???????????? ?????????? ?.?. ?????????, ?????????? ?.?. ????????. ?., 2016. - 412 ?.
Kwok M, Rawstron AC, Varghese A, Evans PA, O'Connor SJ, Doughty C, Newton DJ, Moreton P, Hillmen P
Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016 Dec 15;128(24):2770-2773. Epub 2016 Oct 3.

Prospective One-center Open Label Observational Efficacy & Safety Study of Chlorambucil & Obinutuzumab in Treatment of Unfit Patients With Untreated Chronic Lympho Leukemia With Comorbidities

Details for clinical trial NCT03529227

Clinical trial NCT03529227 - References